Epidemiology of Antisynthetase Syndrome and Risk of Malignancy in a Population-Based Cohort (1998-2019)
An erratum to this article was published (J Rheumatol, 1 Jun 2025 ↗)
Authors' conclusion
ASS is rare, with an incidence of 0.56 per 100,000 population and prevalence of 9.21 per 100,000. In this cohort, incidence was similar between male and female individuals, and was highest in persons aged 50-59 years. None of the patients developed malignancy within 3 years of ASS diagnosis.
Study context
- Population
- Adults with incident antisynthetase syndrome residing in Olmsted County, Minnesota, 1998–20197 [54%] female
- Participants
- 13 adults
- Outcome
- Incidence and prevalence of ASS; malignancy risk following ASS diagnosis
Methodological detailspopulation-based, manual chart review
- Population-based
- Manual chart review
Main finding
As reported in the abstract
Age- and sex-adjusted incidence per 100,000 population
0.56
95% CI 0.25–0.87
Age- and sex-adjusted prevalence per 100,000
9.21
95% CI 3.44–14.98
Observational data: associations, not effects.
Further findings
Malignancy after antisynthetase syndrome (ASS) diagnosis · follow-up interval
- Diagnosed with malignancy within follow-up
- 2 of 13 (15%)
- Diagnosed with malignancy within 3 years of ASS diagnosis
- 0
Survival · median 11.9 (IQR 7.0-13.4) years of follow-up
- Patients alive
- 12/13 (92%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →